(CercleFinance.com) – Janssen, the pharmaceutical subsidiary of Johnson & Johnson, announced on Wednesday that the European Commission has granted conditional marketing authorization to Tecvayli in the treatment of multiple myeloma.
In a press release, J&J specifies that the green light from Brussels is limited to patients with relapsed or refractory multiple myeloma (RRMM), who have received at least three previous treatments, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. , and whose disease progressed during the last treatment.
However, this is the first marketing authorization received worldwide for Tecvayli (teclistamab), a bispecific antibody that targets both B-cell maturation antigen (BCMA), a marker found on myeloma cells multiple, and CD3, on T cells.
Multiple myeloma is an incurable blood cancer that affects a type of white blood cells called plasma cells, which are found in the bone marrow.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
